BIOSTEM TECHNOLOGIES INC
BSEMNASDAQTrading Snapshot
- Day Range
- $3.92 – $4.01
- 52-Week Range
- $3.01 – $10.71
- Volume
- $2.11B
- Avg Volume
- $2.54B
- Shares Outstanding
- 17.0M
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $47M
- Last Q Revenue
- $6M
- P/E Ratio
- -3.3
- P/S Ratio
- -3.5x
- EPS (TTM)
- $-1.18
- Dividend Yield
- 0.00%
Why Investors Own BSEM
- ✓High-growth profile — revenue up +28.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOSTEM TECHNOLOGIES INC
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.